Basal Ganglia Diseases  >>  carbidopa/levodopa  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carbidopa/levodopa / Generic mfg.
NCT00947037: Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study

Withdrawn
2
0
RoW
AP-CD/LD
Intec Pharma Ltd.
Parkinson's Disease
08/12
 
NCT01617135 / 2012-000181-37: Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes

Checkmark MDS 2015
Aug 2015 - Aug 2015: MDS 2015
Checkmark
Jun 2014 - Jun 2014: 
Completed
2
25
Europe, RoW
CVT-301, Placebo, Sinemet (carbidopa/levodopa)
Acorda Therapeutics, Michael J. Fox Foundation for Parkinson's Research
Idiopathic Parkinson's Disease
11/12
12/12
NCT00491998 / 2006-004112-51: PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets

Completed
1/2
27
Europe
V1512, V1512 and Entacapone
Vernalis (R&D) Ltd, Cita NeuroPharmaceuticals, Syneos Health
Parkinson's Disease
11/07
11/07

Download Options